Search results for "PULMONARY"

showing 10 items of 3030 documents

Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach.

2005

Lung is a target organ for the toxicity of inhalated compounds. The respiratory tract is frequently exposed to elevated concentrations of these compounds and become the primary target site for toxicity. Occupational, accidental or prolonged exposure to a great variety of chemicals may result in acute or delayed injury to cells of the respiratory tract. Nevertheless, lung has a significant capability of biotransforming such compounds with the aim of reducing its potential toxicity. In some instances, the biotransformation of a given compound can result in the generation of more reactive, and frequently more toxic, metabolites. Indeed, lung tissue is known to activate pro-carcinogens (i.e. po…

Pulmonary toxicityBiologyToxicologyModels BiologicalPathology and Forensic MedicineCell LineXenobioticsCytochrome P-450 Enzyme SystemmedicineHumansEpoxide hydrolaseLungBiotransformationA549 cellAir PollutantsLungCytochrome P450Cell BiologyGeneral Medicinerespiratory systemCYP2E1medicine.anatomical_structureBiochemistryCell cultureToxicitybiology.proteinExperimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie
researchProduct

Unseeded Elastomeric Single Leaflets Retain Function and Remodel After Implant In Ovine Pulmonary Outflow Tract

2013

Current materials for heart valve replacement and repair are limited by the inability to grow or remodel. Tissue engineered valves offer the potential to overcome these disadvantages by creating living structures, but is limited by the availability of biocompatible scaffold materials with desirable biomechanical properties. We assessed the in vivo performance of a novel scaffold poly(carbonate urethane) urea (PCUU), fabricated by electrospinning and implanted in the pulmonary outflow tract of sheep. PCUU was electrospun into elastomeric sheets of thickness ranging from 120-180 μm. Using cardiopulmonary bypass we replaced the native anterior pulmonary leaflet with an acellular PCUU leaflet. …

Pulmonary valve Tissue engineering Valvular heart disease Molecular Remodeling.
researchProduct

A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample

2011

Lung function measures are heritable traits that predict population morbidity and mortality and are essential for the diagnosis of chronic obstructive pulmonary disease (COPD). Variations in many genes have been reported to affect these traits, but attempts at replication have provided conflicting results. Recently, we undertook a meta-analysis of Genome Wide Association Study (GWAS) results for lung function measures in 20,288 individuals from the general population (the SpiroMeta consortium). OBJECTIVES: To comprehensively analyse previously reported genetic associations with lung function measures, and to investigate whether single nucleotide polymorphisms (SNPs) in these genomic regions…

PulmonologyChronic Obstructive Pulmonary DiseasesEpidemiologyVital Capacitylcsh:MedicineGenome-wide association studyBioinformaticsPDE4DPulmonary function testingPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumePHOSPHODIESTERASE 4D GENElcsh:ScienceLungRISK0303 health scienceseducation.field_of_studyCOPDMultidisciplinaryAlpha 1-antitrypsin deficiencyGreat BritainALPHA(1)-ANTITRYPSIN DEFICIENCYta3141ta3142respiratory system3142 Public health care science environmental and occupational health3. Good healthRespiratory Function Testsmedicine.anatomical_structureGenetic EpidemiologyScience & Technology - Other TopicsMedicineBiological MarkersHEALTHResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyPopulationObstructive pulmonary-disease; Phosphodiesterase 4D gene; Alpha(1)-antitrypsin deficiency; Health; PDE4D; RiskPolymorphism Single NucleotideOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesMeta-Analysis as TopicMolecular geneticsMD MultidisciplinarymedicineGeneticsGenome-Wide Association StudiesHumansGenetic Predisposition to DiseaseeducationBiology030304 developmental biologyAsthmaScience & TechnologyLungMULTIDISCIPLINARY SCIENCESbusiness.industryGenome Humanlcsh:RSmoking Related DisordersSpiroMeta Consortiummedicine.diseaseUnited KingdomAsthmarespiratory tract diseasesGenetics of Diseaselcsh:Qbusiness030217 neurology & neurosurgeryBiomarkersGenome-Wide Association Study
researchProduct

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B…

2016

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organizatio…

Pulmons -- Malalties obstructivesVeterinary medicineAllergyPublished ErratumLANGUEDOC-ROUSSILLONAllergyRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Aparell respiratori -- MalaltiesOPERATIONAL DEFINITIONAlternative medicineReviewChronic respiratory diseasesGLOBAL ALLIANCESYSTEMS MEDICINE0302 clinical medicineMedicine and Health SciencesImmunology and AllergyMACVIA030212 general & internal medicineAIRWAYS ICPLungmedicin och allergiEIP on AHA; European Innovation Partnership on Active and Healthy Ageing; Chronic respiratory diseases; AIRWAYS ICPs; MACVIA; ARIA; Scaling upGINA STRATEGYAIRWAYSUPDATE ARIA 2008Scaling upRespiratory disease:Outras Ciências Agrárias [Ciências Agrárias]3. Good healthChronic respiratory diseaseALLERGIC RHINITISICPsAIRWAYS ICPsGeneral partnershipAction planErratumLife Sciences & BiomedicineAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling upPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling up; Immunology and AllergyEmerging technologiesImmunologyREFERENCE SITESocio-culturalePredictive medicine03 medical and health sciencesEuropean Innovation Partnership on Active and Healthy AgeingNursingCritical success factorJournal Articlemedicineddc:610Science & TechnologyARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSmedicine.diseaseIntegrated careAlliance030228 respiratory systemCiências Agrárias::Outras Ciências Agrárias3121 General medicine internal medicine and other clinical medicineFamily medicineImmunologyHealthy ageingbusinessSEVERE ASTHMA
researchProduct

Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.

2021

Interstitial lung diseases (ILDs) include a large number of diseases and causes with variable outcomes often associated with progressive fibrosis. Although each of the individual fibrosing ILDs are rare, collectively, they affect a considerable number of patients, representing a significant burden of disease. Idiopathic pulmonary fibrosis (IPF) is the typical chronic fibrosing ILD associated with progressive decline in lung. Other fibrosing ILDs are often associated with connective tissues diseases, including rheumatoid arthritis-ILD (RA-ILD) and systemic sclerosis-associated ILD (SSc-ILD), or environmental/drug exposure. Given the vast number of progressive fibrosing ILDs and the dispariti…

QH301-705.5DiseaseReviewbehavioral disciplines and activitiesCatalysisextracellular HSPInorganic ChemistryIdiopathic pulmonary fibrosisFibrosisHeat shock proteinmedicineExtracellularAnimalsHumansinterstitial lung diseasesMolecular Targeted TherapyPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyHeat-Shock ProteinsLungbusiness.industryOrganic Chemistrylung fibrosisCancerGeneral Medicinerespiratory systemmedicine.diseaseIdiopathic Pulmonary FibrosisComputer Science Applicationsrespiratory tract diseasesbody regionsChemistrymedicine.anatomical_structureIPFImmunologyheat shock proteinsDisease ProgressionBiomarker (medicine)biomarkerbusinessLung Diseases InterstitialBiomarkersInternational journal of molecular sciences
researchProduct

Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms

2021

Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number of profibrotic/pro-inflammatory cytokines, such as IL-6, IL-11, and IL-13, among others, which are increased in different ILDs. Similarly, several growth factors over-expressed in ILDs, such as platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-β1), and fibroblast growth factor (FGF) activate JAK/STAT by canonical or non-canonical pathways, which indicates a predominant role of JAK/STAT in ILDs. Between the different JAK/STAT iso…

QH301-705.5medicine.medical_treatmentReviewCatalysisstatInorganic ChemistryPulmonary fibrosismedicineHumansProtein IsoformsPhysical and Theoretical ChemistryBiology (General)STAT3Molecular BiologyProtein Kinase InhibitorsQD1-999SpectroscopyCellular SenescenceJanus KinasesbiologyChemistryGrowth factorInterleukinsinterstitial lung disease (ILD)Organic ChemistryJAK-STAT signaling pathwayGeneral Medicinerespiratory systemmedicine.diseaseEndoplasmic Reticulum StressComputer Science Applicationsrespiratory tract diseasesSTAT Transcription FactorsChemistrysignal transducer and activator of transcription (STAT)biology.proteinCancer researchidiopathic pulmonary fibrosis (IPF)Janus kinaseLung Diseases InterstitialJanus kinases (JAK)Platelet-derived growth factor receptorTransforming growth factorSignal TransductionInternational Journal of Molecular Sciences
researchProduct

Advances in Pulmonary Medicine: Research and Innovations

2019

This book discusses a wide range of investigations and practice-oriented advances in pulmonary medicine and critical care. Pulmonary diseases are a major cause of hospitalization and mortality, affecting millions of people worldwide. Addressing a range of topics, including chronic obstructive pulmonary disease, sleep apnea, and lung cancer, the book offers insights into the disease mechanisms and risk factors, along with practical aspects concerning the maintenance of quality of life, adherence to therapy, and palliative treatment and care. Further, it explores diagnostic and treatment approaches to respiratory dysfunction and respiratory failure, highlighting the beneficial effects of good…

Quality of lifeCoughSleep disordered breathingChronic obstructive pulmonary diseaseRespiratory physiotherapyCancer researchPulmonary infections
researchProduct

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Kinetic evidence for the solubilization of pyridine-2-azo-p-dimethylaniline in alkanediyl-α,ω-bis(dimethylcetylammonium nitrate) surfactants. Role of…

2004

The incorporation of the bidentate ligand pyridine-2-azo-p-dimethylaniline (PADA) into micellar aggregates of the dimeric cationic surfactants propanediyl-, hexanediyl- and dodecanediyl-alpha,omega-bis(dimethylcetylammonium nitrate) (16-3-16,2NO(3)(-), 16-6-16,2NO(3)(-) and 16-12-16,2NO(3)(-), respectively) has been studied at 25 degreesC by examining the kinetics of the complexation reaction of the Ni(II) ion with this ligand. For comparison, cetyltrimethylammonium nitrate ( CTAN), which can be considered as the "monomeric'' surfactant of 16-3-16,2NO(3)(-), has also been used. The kinetic data have shown that, for 16-3-16,2NO(3)(-) and CTAN, at a surfactant concentration below the critical…

Reaction mechanismInorganic chemistryMicelleCATIONIC GEMINI SURFACTANTSCatalysisHydrophobic effectReaction rate constantPulmonary surfactantDIMERIC SURFACTANTSPolymer chemistryMaterials ChemistryWATERELECTRON TRANSFERANGLE NEUTRON SCATTERINGInterfaces (materials) Optical waveguides metal ionsAqueous solutionAGGREGATION PROPERTIESChemistryAQUEOUS SOLUTIONCationic polymerizationGeneral ChemistryANIONIC MICELLESSUBSTITUTED FERROCENESCritical micelle concentrationBROMIDE SURFACTANTSANGLE NEUTRON SCATTERING; CATIONIC GEMINI SURFACTANTS; AQUEOUS SOLUTION; BROMIDE SURFACTANTS; DIMERIC SURFACTANTS; SUBSTITUTED FERROCENES; AGGREGATION PROPERTIES; ELECTRON TRANSFER; ANIONIC MICELLES; WATERNew J. Chem.
researchProduct

Rate-retarding effects of mixed anionic/non-ionic micelles on the alkaline hydrolysis of the chloropentamminocobalt(III) complex

2006

Abstract Rate data for the alkaline hydrolysis of the chloropentaamminecobalt(III) cation in the presence of mixed micelles composed of (i) anionic sodium decylsulphate (SDeS) and non-ionic dodecylpenta(oxyethylene glycol) monoether (C 12 E 5 ) surfactants and (ii) anionic sodium perfluorooctanoate (SPFO) and non-ionic C 12 E 5 surfactants has been obtained at T 298 K and constant electrolyte concentration 0.08 mol dm −3 ([NaOH] = 0.01 mol dm −3 , [NaClO 4 ] = 0.07 mol dm −3 ) over a wide range of total surfactant concentration ( C t ) and anionic mole fraction ( χ ). The critical micelle concentrations (c.m.c.s) of the mixed micelles have been determined over the entire χ range by means of…

Reaction ratechemistry.chemical_compoundColloid and Surface ChemistryReaction rate constantPulmonary surfactantChemistryCritical micelle concentrationInorganic chemistrySodium dodecyl sulfateMole fractionBinding constantMicelleColloids and Surfaces A: Physicochemical and Engineering Aspects
researchProduct